Biodefense and Infectious Disease
Emerging infectious diseases such as Zika virus, influenza, antibiotic resistant bacteria (i.e., superbugs) or respiratory syncytial virus (RSV) continue to pose a threat to public health both in the US and abroad. In addition, certain bacterial or viral infectious agents have the potential to be used for bioterrorism purposes when aerosolized, such as Bacillus anthracis (anthrax) and Yersinia pestis (plague). As a premier infectious disease CRO, we offer a wide range of services to evaluate the immunogenicity, efficacy, potency, and safety of vaccines, antitoxins and therapeutics as medical countermeasures (MCMs) against agents of biological warfare and bioterrorism.
We offer an extensive collection of infectious disease animal models that are available for efficacy testing of therapeutic antibiotics or antivirals and vaccines, including small molecules and biologics. IITRI also offers complete GLP-compliant preclinical vaccine toxicology programs and Animal Rule studies. We are one of the very few labs in the US that offers GLP-compliant BSL-2 and BSL-3 facilities for infectious disease preclinical studies using select agents.
Our laboratory and vivarium space includes Biosafety Level 2 and 3+ facilities, fully functional with the latest equipment to conduct pathogenic agent studies. We are registered with the CDC and USDA for possession and use of select agents and toxins. In addition, we have the distinction of being one of only two non-government laboratories that operates a Department of the Army approved Biological Surety Program.
Our BSL-3 lab houses our bioaerosol generation and aerosol exposure system for aerosol delivery of pathogens or antiinfective treatments. Bioaerosol delivery is used for viral or bacterial challenge studies and therapeutic efficacy studies for antibiotics or antivirals.